Guila DAYAN
Equipe/Team : Environnement Matriciel & Réparation tissulaireCourriel/Mail :
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Téléphone/Phone : +33(0)4-37-65-29-27Fax/Fax : +33(0)4-72-72-26-04Statut/Status : Maitre de Conférences21 Publications/Papers :
[2013] [2012] [2007] [2006] [2005] [2004] [2003] [2002] [1999] [1998] [1997] [1996] [1994]
2013 [Top] 121. The syndecan binding sequence KKLRIKSKEK in laminin ?3 LG4 domain promotes epidermal repair.
Rousselle P, Carulli S, Chajra H, Dayan G, Pin D, Herbage B
(2013) Eur J Dermatol : 2012 [Top] 1
20. Cell surface proteoglycans syndecan-1 and -4 bind overlapping but distinct sites in laminin ?3 LG45 protein domain.
Carulli S, Beck K, Dayan G, Boulesteix S, Lortat-Jacob H, Rousselle P
(2012) J Biol Chem 287 : 12204-16 2007 [Top] 1
19. Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12
Lupien M , Jeyakumar M , Hebert E , Hilmi K , Cotnoir-White D , Loch C , Auger A , Dayan G , Pinard GA , Wurtz JM , Moras D , Katzenellenbogen J , Mader S
(2007) MOLECULAR ENDOCRINOLOGY 21 : 797-816 2006 [Top] 1
18. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
Dayan G, Lupien M, Auger A, Anghel SI, Rocha W, Croisetiere S, Katzenellenbogen JA, Mader S
(2006) Mol Pharmacol 70 : 579-88 2005 [Top] 7
17. Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope?
Labialle S, Dayan G, Michaud M, Barakat S, Rigal D, Baggetto LG
(2005) Semin Oncol 32 : 583-90 16. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.
Baggetto LG, Gambrelle J, Dayan G, Labialle S, Barakat S, Michaud M, Grange JD, Gayet L
(2005) Cancer Treat Rev 31 : 361-79 15. [Multidrug resistance in uveal melanoma].
Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Michaud M, Grange JD, Baggetto LG
(2005) J Fr Ophtalmol 28 : 652-9 14. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, Cogne S, Mazane A, Coleman AW, Rigal D, Baggetto LG
(2005) Biochemistry 44 : 4499-509 13. Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis.
Barakat S, Gayet L, Dayan G, Labialle S, Lazar A, Oleinikov V, Coleman AW, Baggetto LG
(2005) Biochem J 388 : 563-71 12. Uveal melanoma in an 18-year-old African black man.
Gambrelle J, Dayan G, Baggetto LG, Devouassoux-Shisheboran M, Salle M, Labialle S, Gayet L, Barakat S, Kodjikian L, Grange JD
(2005) Acta Ophthalmol Scand 83 : 134-6 11. Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives.
Labialle S, Dayan G, Gambrelle J, Gayet L, Barakat S, Devouassoux-Shisheboran M, Bernaud J, Rigal D, Grange JD, Baggetto LG
(2005) Melanoma Res 15 : 257-66 2004 [Top] 2
10. [Toward monosomy 3 as the main prognosis factor of uveal melanoma: current cytogenetic data].
Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Grange JD, Baggetto LG
(2004) J Fr Ophtalmol 27 : 1061-7 9. New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein.
Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto LG
(2004) Nucleic Acids Res 32 : 3864-76 2003 [Top] 1
8. RU49953: a non-hormonal steroid derivative that potently inhibits P-glycoprotein and reverts cellular multidrug resistance.
Perez-Victorias FJ, Conseil G, Munoz-Martinez F, Perez-Victoria JM, Dayan G, Marsaud V, Castanys S, Gamarro F, Renoir JM, Di Pietro A
(2003) Cell Mol Life Sci 60 : 526-35 2002 [Top] 1
7. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters.
Di Pietro A, Conseil G, Perez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E, Jault JM, De Wet H, Maitrejean M, Comte G, Boumendjel A, Mariotte AM, Dumontet C, McIntosh DB, Goffeau A, Castanys S, Gamarro F, Barron D
(2002) Cell Mol Life Sci 59 : 307-22 1999 [Top] 2
6. Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin.
Perez-Victoria JM, Chiquero MJ, Conseil G, Dayan G, Di Pietro A, Barron D, Castanys S, Gamarro F
(1999) Biochemistry 38 : 1736-43 5. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
Di Pietro A, Dayan G, Conseil G, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H, Jault J
(1999) Braz J Med Biol Res 32 : 925-39 1998 [Top] 1
4. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein.
Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A
(1998) Proc Natl Acad Sci U S A 95 : 9831-6 1997 [Top] 1
3. Binding of steroid modulators to recombinant cytosolic domain from mouse P-glycoprotein in close proximity to the ATP site.
Dayan G, Jault JM, Baubichon-Cortay H, Baggetto LG, Renoir JM, Baulieu EE, Gros P, Di Pietro A
(1997) Biochemistry 36 : 15208-15 1996 [Top] 1
2. Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein. Overexpression, purification, and role of cysteine 430.
Dayan G, Baubichon-Cortay H, Jault JM, Cortay JC, Deleage G, Di Pietro A
(1996) J Biol Chem 271 : 11652-8 1994 [Top] 1
1. Overexpression and purification of the carboxyl-terminal nucleotide-binding domain from mouse P-glycoprotein. Strategic location of a tryptophan residue.
Baubichon-Cortay H, Baggetto LG, Dayan G, Di Pietro A
(1994) J Biol Chem 269 : 22983-9